{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.035","upperLimit":"1.12","value":"0.035"},{"groupId":"OG001","lowerLimit":"0.035","upperLimit":"0.40","value":"0.035"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.035","upperLimit":"0.11","value":"0.035"},{"groupId":"OG001","lowerLimit":"0.035","upperLimit":"0.12","value":"0.035"}]}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.035","upperLimit":"0.11","value":"0.035"},{"groupId":"OG001","lowerLimit":"0.035","upperLimit":"0.08","value":"0.035"}]}],"title":"Day 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.035","upperLimit":"0.47","value":"0.035"},{"groupId":"OG001","lowerLimit":"0.035","upperLimit":"0.12","value":"0.035"}]}],"title":"Day 14"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.035","upperLimit":"0.16","value":"0.035"},{"groupId":"OG001","lowerLimit":"0.035","upperLimit":"0.19","value":"0.035"}]}],"title":"Day 28"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.035","upperLimit":"0.17","value":"0.035"},{"groupId":"OG001","lowerLimit":"0.035","upperLimit":"0.22","value":"0.035"}]}],"title":"Day 56"}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"During the main CS21 study (NCT00295750), leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.\n\nStarting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.\n\nFollowing the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.","id":"OG000","title":"Leuprolide 7.5 mg/ Degarelix 240/80 mg"},{"description":"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.\n\nStarting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.\n\nFollowing the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.","id":"OG001","title":"Leuprolide 7.5 mg/ Degarelix 240/160 mg"}],"paramType":"MEDIAN","populationDescription":"All participants who received leuprolide in the main CS21 study (NCT00295750) and were switched over to degarelix in the CS21A extension study.","reportingStatus":"POSTED","timeFrame":"From time of switch to Day 56","title":"Serum Levels of Luteinizing Hormone (LH) From the Time of Switch From Leuprolide to Degarelix to Day 56","type":"SECONDARY","unitOfMeasure":"International units/Liter (IU/L)"}